Pierrel Valuation
Is 2FJ0 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 2FJ0 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 2FJ0's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 2FJ0's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 2FJ0?
Key metric: As 2FJ0 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 2FJ0's PE Ratio? | |
|---|---|
| PE Ratio | 29.9x |
| Earnings | €3.11m |
| Market Cap | €92.83m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 4.3x |
| Enterprise Value/EBITDA | 22.5x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does 2FJ0's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 10.4x | ||
PSG PharmaSGP Holding | 16.1x | 14.6% | €297.4m |
93M1 MPH Health Care | 0.8x | -65.7% | €98.5m |
DMP Dermapharm Holding | 20.5x | 18.1% | €1.9b |
8049 Jilin Province Huinan Changlong Bio-pharmacy | 4.2x | n/a | HK$767.5m |
2FJ0 Pierrel | 29.9x | n/a | €92.8m |
Price-To-Earnings vs Peers: 2FJ0 is expensive based on its Price-To-Earnings Ratio (29.9x) compared to the peer average (13.9x).
Price to Earnings Ratio vs Industry
How does 2FJ0's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?
| 1 Company | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 1 Company | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: 2FJ0 is expensive based on its Price-To-Earnings Ratio (29.9x) compared to the European Pharmaceuticals industry average (23.4x).
Price to Earnings Ratio vs Fair Ratio
What is 2FJ0's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 29.9x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 2FJ0's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Aspen Pharmacare Holdings
R76.0b
Manufactures and supplies specialty and branded pharmaceutical products worldwide.
LDZA
R8.90
7D
-4.3%
1Y
4.7%
Fortrea Holdings
US$1.7b
A contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide.
K67
US$18.70
7D
-14.2%
1Y
-35.1%
Almirall
€1.8b
A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.
E2Z
€8.44
7D
-3.9%
1Y
-4.0%